Linked Life Data

19300261

Source:http://linkedlifedata.com/resource/pubmed/id/19300261

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-3-24
pubmed:abstractText
This review will discuss a potentially more effective treatment for retinopathy of prematurity (ROP) with fewer acute and long-term complications. Avastin (bevacizumab) therapy is a promising anti-vascular endothelial growth factor (anti-VEGF) administered directly into the vitreous.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1531-698X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
182-7
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Antivascular endothelial growth factor for retinopathy of prematurity.
pubmed:affiliation
Department of Ophthalmology and Visual Science, University of Texas Health Science Center, Houston University of Texas-Houston Medical School, 6410 Fannin St., Houston, TX 77030-5204, USA. Helen.A.Mintz-Hittner@uth.tmc.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural